Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Luxturna Model: Spark’s Approach To Retinal Disease Endpoint Embraced In Gene Therapy Guidance

Jul 12 2018

• By Sue Sutter

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes

Related Content

Gene Therapies Need Long-Term Follow-Up Plan From Outset Or Risk Clinical Hold

Jul 12 2018

Familiar Principles In Gene Therapy Guidance For Rare Diseases

Jul 12 2018

How To Build An Endpoint: Spark Designed Testing Maze To Study Rare Vision Loss

Oct 15 2017

Spark's Gene Therapy Luxturna Sails Through US FDA Panel

Oct 13 2017

Spark's Early Christmas Present: US FDA Approves Luxturna For Vision Loss

Dec 19 2017

Gene Therapy Guidances Will Focus On Specific Diseases, Gottlieb Says

Dec 07 2017

Related Companies

Spark Therapeutics, Inc.

Additional Topics

United States Regenerative Medicine Drug Approval Standards Regulation Ophthalmic BioPharmaceutical

More from Cell & Gene Therapies

More from Advanced Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window